Mesenchymal stem cells ameliorate experimental autoimmune hepatitis by activation of the programmed death 1 pathway

Immunology Letters

Volumn 162, Issue 2, 2014, Pages 222-228

  Chen, Yi ^a   Chen, Si ^a   Liu, Li Yuan ^a   Zou, Zhuo Lin ^a   Cai, Yi Jing ^a   Wang, Jin Guo ^a   Chen, Bi ^a   Xu, Lan Man ^a   Lin, Zhuo ^a   Wang, Xiao Dong ^a   Chen, Yong Ping ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Autoimmune hepatitis; Interleukin 17; Interleukin 23; Mesenchymal stem cells; Programmed death ligand 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 17; INTERLEUKIN 23; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, MOUSE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL AUTOIMMUNE HEPATITIS; EXPERIMENTAL HEPATITIS; GENE ACTIVATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION; LIVER INJURY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BLOOD; DISEASE MODEL; GENE EXPRESSION REGULATION; HEPATITIS, AUTOIMMUNE; IMMUNOLOGY; MESENCHYMAL STROMA CELL; PATHOLOGY;

ANIMALS; ANTIGENS, CD274; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HEPATITIS, AUTOIMMUNE; INTERLEUKIN-17; INTERLEUKIN-23; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE;

EID: 84912532063     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.10.021     Document Type: Article

References (53)

1. Zachou K., Rigopoulou E., Dalekos G.N. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmun Dis 2004, 1:2.
2. Vierling J.M. Diagnosis and treatment of autoimmune hepatitis. Curr Gastroenterol Rep 2012, 14:25-36.
3. Ichiki Y., Aoki C.A., Bowlus C.L., Shimoda S., Ishibashi H., Gershwin M.E. T cell immunity in autoimmune hepatitis. Autoimmun Rev 2005, 4:315-321.
4. Krawitt E.L. Autoimmune hepatitis. N Engl J Med 2006, 354:54-66.
5. Selvarajah V., Montano-Loza A.J., Czaja A.J. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther 2012, 36:691-707.
6. Djouad F., Bouffi C., Ghannam S., Noel D., Jorgensen C. Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol 2009, 5:392-399.
7. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30:42-48.
8. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102:3837-3844.
9. Wang J., Wang G., Sun B., Li H., Mu L., Wang Q., et al. Interleukin-27 suppresses experimental autoimmune encephalomyelitis during bone marrow stromal cell treatment. J Autoimmun 2008, 30:222-229.
10. Bouffi C., Bony C., Courties G., Jorgensen C., Noel D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS ONE 2010, 5:e14247.
11. Ghannam S., Pene J., Moquet-Torcy G., Jorgensen C., Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol (Baltimore, MD: 1950) 2010, 185:302-312.
12. Kim N., Cho S.G. Clinical applications of mesenchymal stem cells. Korean J Intern Med 2013, 28:387-402.
13. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8:726-736.
14. Sharpe A.H., Freeman G.J. The B7-CD28 superfamily. Nat Rev Immunol 2002, 2:116-126.
15. Carreno B.M., Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002, 20:29-53.
16. Riley J.L. PD-1 signaling in primary T cells. Immunol Rev 2009, 229:114-125.
17. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000.
18. Oikawa T., Takahashi H., Ishikawa T., Hokari A., Otsuki N., Azuma M., et al. Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. Pathol Int 2007, 57:485-492.
19. Fife B.T., Pauken K.E. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann NY Acad Sci 2011, 1217:45-59.
20. Sheng H., Wang Y., Jin Y., Zhang Q., Zhang Y., Wang L., et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 2008, 18:846-857.
21. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278:1910-1914.
22. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu Rev Immunol 2009, 27:485-517.
23. Haak S., Gyulveszi G., Becher B. Th17 cells in autoimmune disease: changing the verdict. Immunotherapy 2009, 1:199-203.
24. Lafdil F., Wang H., Park O., Zhang W., Moritoki Y., Yin S., et al. Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production. Gastroenterology 2009, 137:2125-2135. e2121-2.
25. Nagata T., McKinley L., Peschon J.J., Alcorn J.F., Aujla S.J., Kolls J.K. Requirement of IL-17RA in Con A induced hepatitis and negative regulation of IL-17 production in mouse T cells. J Immunol 2008, 181:7473-7479.
26. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000.
27. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
28. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
29. Gheita T.A., El Gazzar I.I., El-Fishawy H.S., Aboul-Ezz M.A., Kenawy S.A. Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results. Clin Rheumatol 2014.
30. D'Addio F., Riella L.V., Mfarrej B.G., Chabtini L., Adams L.T., Yeung M., et al. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol (Baltimore, MD: 1950) 2011, 187:4530-4541.
31. Luz-Crawford P., Noel D., Fernandez X., Khoury M., Figueroa F., Carrion F., et al. Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLOS ONE 2012, 7:e45272.
32. Lohse A.W., Dienes H.P., Meyer zum Buschenfelde K.H. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 1998, 27:1536-1543.
33. Lohse A.W., Manns M., Dienes H.P., Meyer zum Buschenfelde K.H., Cohen I.R. Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology 1990, 11:24-30.
34. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
35. Schramm C., Protschka M., Kohler H.H., Podlech J., Reddehase M.J., Schirmacher P., et al. Impairment of TGF-beta signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice. Am J Physiol: Gastrointest Liver Physiol 2003, 284:G525-G535.
36. Shi Y., Su J., Roberts A.I., Shou P., Rabson A.B., Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 2012, 33:136-143.
37. Yanez R., Lamana M.L., Garcia-Castro J., Colmenero I., Ramirez M., Bueren J.A. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006, 24:2582-2591.
38. Eggenhofer E., Renner P., Soeder Y., Popp F.C., Hoogduijn M.J., Geissler E.K., et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol 2011, 25:141-147.
39. Peister A., Mellad J.A., Larson B.L., Hall B.M., Gibson L.F., Prockop D.J. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 2004, 103:1662-1668.
40. Lin C.S., Ning H., Lin G., Lue T.F. Is CD34 truly a negative marker for mesenchymal stromal cells. Cytotherapy 2012, 14:1159-1163.
41. Simmons P.J., Torok-Storb B. CD34 expression by stromal precursors in normal human adult bone marrow. Blood 1991, 78:2848-2853.
42. Kaiser S., Hackanson B., Follo M., Mehlhorn A., Geiger K., Ihorst G., et al. BM cells giving rise to MSC in culture have a heterogeneous CD34 and CD45 phenotype. Cytotherapy 2007, 9:439-450.
43. Cao J., Liu F.X., Yu M.X. Expression of programmed death 1 and its ligands in the liver of autoimmune hepatitis C57BL/6 mice. Chin Med J (Engl) 2009.
44. Kassel R., Cruise M.W., Iezzoni J.C., Taylor N.A., Pruett T.L., Hahn Y.S. Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology 2009, 50:1625-1637.
45. Luz-Crawford P., Kurte M., Bravo-Alegria J., Contreras R., Nova-Lamperti E., Tejedor G., et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther 2013, 4:65.
46. Augello A., Tasso R., Negrini S.M., Amateis A., Indiveri F., Cancedda R., et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005, 35:1482-1490.
47. Hirahara K., Ghoreschi K., Yang X.P., Takahashi H., Laurence A., Vahedi G., et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 2012, 36:1017-1030.
48. Francisco L.M., Sage P.T., Sharpe A.H. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010, 236:219-242.
49. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
50. Croxford A.L., Mair F., Becher B. IL-23: one cytokine in control of autoimmunity. Eur J Immunol 2012, 42:2263-2273.
51. Xu M., Morishima N., Mizoguchi I., Chiba Y., Fujita K., Kuroda M., et al. Regulation of the development of acute hepatitis by IL-23 through IL-22 and IL-17 production. Eur J Immunol 2011, 41:2828-2839.
52. Olewicz-Gawlik A., Danczak-Pazdrowska A., Kuznar-Kaminska B., Gornowicz-Porowska J., Katulska K., Trzybulska D., et al. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis. Int J Rheum Dis 2014.
53. Liu P., Xuan X., Zhu J., Guan S., Du Y., Li Q. Therapeutic effect of allogenic bone marrow mesenchymal stem cell transplantation on EAE mouse. Xi bao yu fen zi mian yi xue za zhi 2013, 29:798-801.